CN1618448A - 一种具有治疗骨性关节炎作用的药物组合物及其制备方法 - Google Patents
一种具有治疗骨性关节炎作用的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1618448A CN1618448A CN 200310115333 CN200310115333A CN1618448A CN 1618448 A CN1618448 A CN 1618448A CN 200310115333 CN200310115333 CN 200310115333 CN 200310115333 A CN200310115333 A CN 200310115333A CN 1618448 A CN1618448 A CN 1618448A
- Authority
- CN
- China
- Prior art keywords
- radix
- extract
- consumption
- effective ingredient
- described pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 238000000034 method Methods 0.000 title claims description 57
- 229940079593 drug Drugs 0.000 title claims description 44
- 239000000203 mixture Substances 0.000 title claims description 24
- 206010003246 arthritis Diseases 0.000 title claims description 8
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 36
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 36
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 24
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 6
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000000284 extract Substances 0.000 claims description 114
- 238000002360 preparation method Methods 0.000 claims description 82
- 239000008280 blood Substances 0.000 claims description 60
- 210000004369 blood Anatomy 0.000 claims description 59
- 239000007788 liquid Substances 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000009636 Huang Qi Substances 0.000 claims description 37
- 239000004615 ingredient Substances 0.000 claims description 37
- 244000131316 Panax pseudoginseng Species 0.000 claims description 35
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 33
- 239000012567 medical material Substances 0.000 claims description 32
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 31
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 31
- 235000008434 ginseng Nutrition 0.000 claims description 31
- 210000004185 liver Anatomy 0.000 claims description 31
- 241000903946 Clematidis Species 0.000 claims description 25
- 208000002193 Pain Diseases 0.000 claims description 25
- 230000036407 pain Effects 0.000 claims description 25
- 210000003205 muscle Anatomy 0.000 claims description 23
- -1 glycosides compound Chemical class 0.000 claims description 22
- 210000003734 kidney Anatomy 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 13
- 238000012545 processing Methods 0.000 claims description 13
- 238000007670 refining Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 238000004440 column chromatography Methods 0.000 claims description 12
- 230000007812 deficiency Effects 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 229930182493 triterpene saponin Natural products 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- 210000003462 vein Anatomy 0.000 claims description 10
- 241000721047 Danaus plexippus Species 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 230000008961 swelling Effects 0.000 claims description 9
- 238000000151 deposition Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 7
- 235000020710 ginseng extract Nutrition 0.000 claims description 7
- 210000000629 knee joint Anatomy 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 5
- 239000009480 Radix clematidis extract Substances 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 230000008414 cartilage metabolism Effects 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 5
- 230000004089 microcirculation Effects 0.000 claims description 5
- 238000005325 percolation Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical group C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000012869 ethanol precipitation Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical group C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 241001256368 Clematis chinensis Species 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000002785 anti-thrombosis Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000002131 composite material Substances 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 241000700159 Rattus Species 0.000 description 28
- 230000017531 blood circulation Effects 0.000 description 22
- 230000037396 body weight Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100021253 Antileukoproteinase Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 8
- 229960000452 diethylstilbestrol Drugs 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- JCZPMGDSEAFWDY-MGCNEYSASA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO JCZPMGDSEAFWDY-MGCNEYSASA-N 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 5
- 229920001503 Glucan Polymers 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 229960002442 glucosamine Drugs 0.000 description 5
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 108010052989 Naphthol AS D Esterase Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 241000746998 Tragus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000264 venule Anatomy 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000008727 tongluo Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量 | 鼠数 | Hb(g/ld) | |||
(g/kg) | (只) | 失血前 | 失血后 | 给药后 | 增加值 | |
正常对照 | -- | 10 | 17.45±1.30 | 17.37±1.36 | 17.19±1.37 | -0.18±0.72 |
失血对照 | -- | 10 | 17.36±1.79 | 12.81±1.70** | 90±1.62** | 2.09±0.70** |
发明组合物制剂 | 20.0 | 10 | 17.33±1.20 | 12.64±1.45** | 16.40±1.22# | 3.76±1.94# |
10.0 | 10 | 17.41±1 29 | 12.81±1.11** | 15.55±1.25 | 2.84±1.56 | |
5.0 | 10 | 17.26±1.43 | 12.78±1.65** | 15.02±0.81 | 2.24±1.83 | |
壮骨丸 | 2.6 | 10 | 17.55±1.82 | 12.65±1.24** | 15.06±1.63 | 2.41±2.04 |
组别 | 剂量(g/kg) | 动物数(只) | 静脉注射5%葡聚糖后变化差值 | 恢复时间(分) | ||||
血流速度 | 管径(格) | 开放数 | 交合点 | |||||
对照 | 10 | -3.1±0.61 | -0.4±0.70 | 0 | 0 | 17.85±8.87 | ||
阿斯匹林 | 0.03 | 10 | -1.2±1.03*** | 0.6±0.82** | 0 | 0 | 1.00±0.85*** | |
消栓通络 | 4.5 | 10 | -2.0±0.69** | 0.4±1.25 | 0.1±0.32 | 0 | 1.92±1.58*** | |
骨痛清冲剂 | 大剂量 | 20.0 | 10 | -1.2±1.55** | 0.2±0.44* | 0 | 0 | 0.85±0.94*** |
中剂量小剂量 | 10.05.0 | 1010 | -2.0±1.05*-2.2±0.63** | 0.0±0.830.2±0.72 | 0.2±0.630 | 00 | 1.20±0.82***3.05±3.04*** |
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101153330A CN100490836C (zh) | 2003-11-19 | 2003-11-19 | 一种具有治疗骨性关节炎作用的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101153330A CN100490836C (zh) | 2003-11-19 | 2003-11-19 | 一种具有治疗骨性关节炎作用的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1618448A true CN1618448A (zh) | 2005-05-25 |
CN100490836C CN100490836C (zh) | 2009-05-27 |
Family
ID=34760396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101153330A Expired - Lifetime CN100490836C (zh) | 2003-11-19 | 2003-11-19 | 一种具有治疗骨性关节炎作用的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100490836C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579634A (zh) * | 2012-02-23 | 2012-07-18 | 熊桂华 | 治疗膝关节骨性关节炎的外用中药组合物 |
CN102908510A (zh) * | 2012-11-14 | 2013-02-06 | 牛福文 | 一种治疗膝关节骨性关节炎的汤剂 |
CN103656120A (zh) * | 2012-09-24 | 2014-03-26 | 天津瑞贝特科技发展有限公司 | 具有止血、补血功效的畜用中药组合物及其制备方法 |
CN103705701A (zh) * | 2013-12-27 | 2014-04-09 | 纪忠义 | 一种治疗膝关节骨性关节炎的中药制剂 |
CN104000909A (zh) * | 2014-05-27 | 2014-08-27 | 朱艳茹 | 一种治疗腰间盘突出的中药 |
CN105148179A (zh) * | 2015-08-12 | 2015-12-16 | 孙国栋 | 一种治疗膝关节骨性关节炎的外用药物及使用方法 |
CN107260941A (zh) * | 2017-08-16 | 2017-10-20 | 河北瑞晖动物药业有限公司 | 一种关节止痛舒筋活络制剂 |
CN107260907A (zh) * | 2017-07-27 | 2017-10-20 | 何程膳 | 一种抗菌消炎中药组合物及其制备方法和应用 |
CN109172751A (zh) * | 2018-11-14 | 2019-01-11 | 山东中医药大学 | 一种膝骨关节炎中药复原修复药酒及其制备方法 |
CN113069463A (zh) * | 2021-04-09 | 2021-07-06 | 甘肃中医药大学 | 富硒黄芪皂苷在减缓软骨细胞退变上的应用 |
-
2003
- 2003-11-19 CN CNB2003101153330A patent/CN100490836C/zh not_active Expired - Lifetime
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102579634A (zh) * | 2012-02-23 | 2012-07-18 | 熊桂华 | 治疗膝关节骨性关节炎的外用中药组合物 |
CN102579634B (zh) * | 2012-02-23 | 2014-10-08 | 熊桂华 | 治疗膝关节骨性关节炎的外用中药组合物 |
CN103656120A (zh) * | 2012-09-24 | 2014-03-26 | 天津瑞贝特科技发展有限公司 | 具有止血、补血功效的畜用中药组合物及其制备方法 |
CN103536755B (zh) * | 2012-11-14 | 2015-11-25 | 李萍 | 一种治疗膝关节骨性关节炎的汤剂的制备方法 |
CN103536755A (zh) * | 2012-11-14 | 2014-01-29 | 牛福文 | 一种治疗膝关节骨性关节炎的汤剂的制备方法 |
CN102908510B (zh) * | 2012-11-14 | 2014-01-15 | 牛福文 | 一种治疗膝关节骨性关节炎的汤剂 |
CN102908510A (zh) * | 2012-11-14 | 2013-02-06 | 牛福文 | 一种治疗膝关节骨性关节炎的汤剂 |
CN103705701A (zh) * | 2013-12-27 | 2014-04-09 | 纪忠义 | 一种治疗膝关节骨性关节炎的中药制剂 |
CN103705701B (zh) * | 2013-12-27 | 2016-06-08 | 纪忠义 | 一种治疗膝关节骨性关节炎的中药制剂 |
CN104000909A (zh) * | 2014-05-27 | 2014-08-27 | 朱艳茹 | 一种治疗腰间盘突出的中药 |
CN105148179A (zh) * | 2015-08-12 | 2015-12-16 | 孙国栋 | 一种治疗膝关节骨性关节炎的外用药物及使用方法 |
CN107260907A (zh) * | 2017-07-27 | 2017-10-20 | 何程膳 | 一种抗菌消炎中药组合物及其制备方法和应用 |
CN107260941A (zh) * | 2017-08-16 | 2017-10-20 | 河北瑞晖动物药业有限公司 | 一种关节止痛舒筋活络制剂 |
CN109172751A (zh) * | 2018-11-14 | 2019-01-11 | 山东中医药大学 | 一种膝骨关节炎中药复原修复药酒及其制备方法 |
CN109172751B (zh) * | 2018-11-14 | 2021-07-16 | 山东中医药大学 | 一种膝骨关节炎中药复原修复药酒及其制备方法 |
CN113069463A (zh) * | 2021-04-09 | 2021-07-06 | 甘肃中医药大学 | 富硒黄芪皂苷在减缓软骨细胞退变上的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100490836C (zh) | 2009-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1319575C (zh) | 一种治疗跌打损伤的中药组合物及其制备方法和用途 | |
CN1292788C (zh) | 一种治疗男女不育症的中药组合物 | |
CN1850249A (zh) | 一种具有止咳平喘作用的组合物及其制备方法 | |
CN1778383A (zh) | 关节炎用草药制剂 | |
CN1660355A (zh) | 一种治疗跌打损伤、风湿骨痛的中药制剂及其制备方法 | |
CN1733186A (zh) | 治疗急慢性软组织损伤的外用药物及其制备方法 | |
CN1618448A (zh) | 一种具有治疗骨性关节炎作用的药物组合物及其制备方法 | |
CN1709497A (zh) | 一种苗药组合物及其应用 | |
CN1698816A (zh) | 一种消肿止痛涂膜剂及其制备方法 | |
CN1039286C (zh) | 一种具有抗衰老作用的强力抗老中成药的生产方法 | |
CN1698713A (zh) | 一种治疗风湿痹痛的复方风湿宁组合物及制剂 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1239193C (zh) | 一种治疗三叉神经痛的中药及其制备方法 | |
CN1201805C (zh) | 一种用于放化疗减毒增效的药物组合物及其制备方法 | |
CN1232267C (zh) | 用于治疗脑血管疾病的组合物及其制备方法和应用 | |
CN100350928C (zh) | 一种治疗脑中风的脑血栓泡腾片及其制备方法 | |
CN1745788A (zh) | 一种治疗小儿腹泻的中药制剂及制备方法 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1650996A (zh) | 一种药物组合物及其制备方法和应用 | |
CN1803162A (zh) | 一种治疗鼻科疾病的药物组合物及其制备方法 | |
CN101057954A (zh) | 一种治疗小中风的中药复方及其制备方法 | |
CN1562144A (zh) | 治疗肠易激综合症的中药组合物及其制备方法 | |
CN1745808A (zh) | 一种慢性前列腺炎的中药组合物及其制备方法 | |
CN1634353A (zh) | 一种治疗脉管炎、硬皮病及动脉硬化性下肢血管闭塞症药物 | |
CN1634503A (zh) | 一种治疗胃痛的药物组合物、制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Chen Hua Document name: Notice of publication of application for patent for invention |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Han Bin Document name: Notice of publication of application for patent for invention |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO., L Free format text: FORMER NAME: SHUANGHE PHARMACEUTICAL CO., LTD., BEIJING |
|
CP01 | Change in the name or title of a patent holder |
Address after: Two road 100102 Beijing city Chaoyang District Wangjing Lizedong No. 1 Research Institute of the Ministry of scientific research DCPC Patentee after: CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL Co.,Ltd. Address before: Two road 100102 Beijing city Chaoyang District Wangjing Lizedong No. 1 Research Institute of the Ministry of scientific research DCPC Patentee before: BEIJING DOUBLE-CRANE PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20090527 |
|
CX01 | Expiry of patent term |